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INTRODUCTION
Although breast conserving surgery (BCS) and irradia-
tion is now considered as the preferable treatment method
for patients with stage I and II breast cancer, some con-
troversial issues regarding patient eligibility, radiotherapy
volume, necessity of boost, and optimal combination of
chemotherapy have not been solved yet. As for radio-
therapy volume, the conventional approach is whole
breast irradiation, typically followed by a boost to the
primary tumor bed. It is controversial as to whether nodal
areas should also be irradiated. 
Since 1991, our institution has instituted a team ap-
proach for breast conservation treatment and we previ-
ously reported our radiation technique and short term
follow-up result.(1,2) As we started breast conserving
treatment (BCT) after a National Institutes of Health
(NIH) consensus conference(3) in 1990, we followed rec-
ommended radiotherapy techniques at that time and had
consistently applied the treatment during that period to
the patients reported in the current study.
As long-term follow-up is warranted for diseases with a
long natural history such as breast cancer, we performed
a retrospective analysis of long-term results for patients
receiving BCT with early breast cancer. We analyzed the
patterns of recurrence and the factors affecting recur-
rences. We also assessed the appropriateness of radio-
therapy technique with a special interest in radiotherapy
volume. 
Purpose: To assess the appropriateness of radiotherapy
volume for patients receiving breast-conserving treatment
(BCT) through analysis of recurrence pattern and factors
affecting recurrence. Methods: From 1991 to 1996, 362
patients who received BCT were retrospectively evaluated.
The radiation volume was the involved breast alone in the
patients with less than 4 positive axillary lymph nodes (LNs),
and breast and supraclavicular fossa in patients with 4 or
more positive axillary LNs. The median follow-up period was
123 months (range, 3-169 months). Results: Ten-year over-
all, disease-free, local recurrence-free, and regional recur-
rence-free survival rates were 86.2%, 82.2%, 95.9%, and
95.2%, respectively. Among 310 patients receiving radio-
therapy on the breast alone, 15 (4.8%) had regional recur-
rence. In particular, patients with inner quadrant lesions had
high regional recurrence rates (11/98, 11.2%) (p <0.001).
Conclusion: These low local recurrence rates may reveal
that the current radiotherapy technique was successful.
However, in cases of inner quadrant lesions, there were a
considerable number of regional recurrences, even in N0
cases. This may suggest a potential role for irradiation on
regional LNs in this group.
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METHODS
Patient characteristics
Between 1991 and 1996, 362 patients with clinical stage
I or II breast cancer were treated with conservative surgery
and radiation therapy at Yonsei Cancer Center. Patients
with synchronous or metachronous breast cancer were
excluded. The median follow-up period was 123 months
(range, 3-169 months). 
Patient characteristics are summarized in Table 1. The
age distribution was 23-80 yr with a median age of 44 yr.
The 2002 American Joint Committee on Cancer (AJCC)
tumor staging system was used for cancer staging. Two
hundred five (56.6%) patients had T1 lesions and the others
had T2 lesions. Two hundred forty-two (66.8%) patients
were N0. Eighty-one patients had 1 to 3 axillary lymph
nodes (LNs) involved with the disease while 38 patients
had 4 or more LNs involved with the disease.
Conservative surgery
All patients underwent lumpectomy or quadrantectomy.
Axillary LN dissection was performed in 361 (99.7%) pati-
ents. The median number of dissected LNs was 15 (range,
3-46). Thirteen (3.6%) cases had positive resection margins. 
Radiation therapy
All patients were treated with radiotherapy using tan-
gential fields directed at the whole breast after conser-
vative surgery. Radiation was administered using 4-10
MV X-ray linear accelerators. Whole breast dose was
50.4 Gy (range, 45-55.8 Gy) with 1.8-2 Gy per fraction.
Tumor bed boost was performed with a 9-12 MeV electron
beam. The median boost dose was 10 Gy (range, 10-20
Gy). In cases with positive or close resection margins,
total radiation dose including boost dose was increased
to 65 Gy. Irradiated volume was the involved breast alone
with or without supraclavicular (SCL) fossa in most pati-
ents. Patients with 4 or more positive axillary LNs received
SCL fossa irradiation. In cases of incomplete axillary LN
dissection or extracapsular LN extension, we irradiated
the axilla using posterior boost beam. Internal mammary
nodes (IMNs) were not irradiated.
Chemotherapy
Systemic therapy was delivered at the discretion of the
medical oncologist involved in each case. One hundred
sixty-eight (46.4%) patients with positive axillary LNs
or poor prognostic factors such as high nuclear or histo-
logical grades received chemotherapy. Cyclophosphamide,
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Table 1. Patients and tumor characteristics (n=362)
Variables No. of patients %
Age (yr)*
≤35 65 18
>35 297 82
Menopausal status
Premenopause 249 68.8
Postmenopause 113 31.2
Histology
Invasive ductal carcinoma 325 89.8
Medullary 23 6.4
Mucinous 4 1.1
Tubular 3 0.8
Invasive lobular 7 1.9
Sites of primary tumor
UIQ 99 27.3
UOQ 218 60.2
LIQ 20 5.5
LOQ 25 6.9
pT stage
T1 205 56.6
T2 157 43.4
pN stage
N0 242 66.8
N1  1-3 positive 81 22.4
N2  4-9 25 6.9
N3  ≥10 13 3.6
Unknown 1 0.3
AJCC staging (2002)
I 153 42.3
IIa 129 35.6
IIb 41 11.3
IIIa 25 6.9
IIIc 13 3.6
Unknown 1 0.3
Volume of radiotherapy
Breast alone 310 85.6
Breast+SCL 36 9.9
Breast+SCL+axilla 16 4.4
Chemotherapy
No 194 53.3
Yes 168 46.4
UIQ=upper inner quadrant; UOQ=upper outer quadrant; LIQ=lower
inner quadrant; LOQ=lower outer quadrant; AJCC=American Joint
Committee on Cancer; SCL=supraclavicular.
*Median (range)=44 yr (23-80 yr).
methotrexate, and 5-fluorouracil (CMF) or 5-fluorouracil,
Adriamycin, and cyclophosphamide (FAC) regimens were
administered in 168 (46.4%) patients. Most patients started
chemotherapy after recovering from surgery, received 1
or 3 cycles of chemotherapy before radiotherapy, and
completed chemotherapy after radiotherapy. No patients
received chemotherapy concomitantly with radiotherapy. 
Follow-up method
Patients were followed every 3 months for 2 yr. Post-
radiotherapy mammograms were taken at 6 months after
radiotherapy and annually thereafter. Local failure was
defined as treatment failure that occurred anywhere with-
in treated breast and classified as 1) true recurrence,
defined as being within the primary tumor site or the
boost volume of the treated breast; 2) marginal miss,
defined as being near the boost volume; 3) elsewhere
recurrence, defined as being within treated breast except
1) and 2); or 4) skin recurrence, defined as being the
skin of the treated breast.(4) Regional failure was defined
as failure that occurred in the ipsilateral axillary, SCL,
infraclavicular, IMN regions, and/or level III LN of ipsi-
lateral neck. Contralateral breast recurrence was defined
as the occurrence of a second, independent primary breast
cancer in the ocontralateral breast after the initial diag-
nosis of breast cancer.
Statistical analysis
Overall and disease-free survivals were calculated using
the Kaplan-Meier method, with the time period begin-
ning at the time of surgery. Factors potentially affecting
regional recurrence were evaluated in univariate analysis
using log-rank test. Cox proportional hazards model was
used for multivariate analysis.
RESULTS
Survival analysis 
Ten-year overall, cause-specific, disease-free, local
recurrence-free, regional recurrence-free, and distant
recurrence-free survival rates were 86.2%, 87.3%, 82.2%,
95.9%, 95.2%, and 86.9%, respectively (Figure 1). Ten-
year overall survival rates were 90.5%, 89.5%, 80.3%,
64.9%, and 67.1 % for stage I, IIa, IIb, IIIa, and IIIc, res-
pectively (Figure 2), while disease-free survival rates were
89.3%, 84.9%, 74.8%, 67.2%, and 38.5%, respectively. 
Patterns of failure
Local failures were noted in 14 (3.8%) patients at 3-
106 months (median, 23.5 months) after treatment. Ten
patients had local recurrence alone, 1 had local and regi-
onal recurrence, and 3 had local and distant recurrence.
Among them, there were 4 with true recurrence, 2 with
marginal miss, 3 with elsewhere recurrence, and 5 with
skin recurrence. All patients with local recurrence only
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Figure 1. Kaplan-Meier plots of overall, cause-specific, and dis-
ease-free survival. Ten-year survival rates were 86.2%, 87.3%,
and 82.2%, respectively.
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Figure 2. Overall survival rate according to stage.
received salvage operation and showed no recurrence
thereafter. Any patients with positive resection margin
didn’t have local recurrence. All local failures, except 1,
occurred within 5 yr, and all skin recurrences occurred
within 1 yr after treatment. In patients with skin recur-
rences, the number of involved axillary LNs was 3, 9, 11,
18, and 39. Three of 13 patients with 10 or more positive
LNs (23.0%) developed skin recurrences. 
Regional failure occurred in 17 (4.6%) patients at 3-90
months (median, 36 months) after treatment. Among
them, 11 also had local or distant metastasis. All regional
failures occurred within 4 yr after treatment, except 1 SCL
LN recurrence found at 90 months. The site of regional
recurrence was in the SCL LN in 11 patients, in the IMN
in 2 patients, and both in the SCL LN and IMN in 2 pati-
ents. There was no axillary LN recurrence. There were 7
cases with contralateral breast recurrence. Distant fail-
ures were noted in 40 (11.0%) patients at 3-114 months
(median, 36 months) after treatment (Table 2). The most
common site was the lung (50.0%). Ten patients with dis-
tant metastasis were deceased within 5 yr. Among the 6
patients with only regional recurrence, 2 refused treat-
ment and were deceased in 2 yr while the remaining 4
received systemic chemotherapy and radiotherapy at the
site of regional recurrence.
Prognostic factors affecting overall and disease-
free survival
The results of univariate and multivariate analyses
using log-rank test for overall and disease-free survival
are shown in Table 3. For overall survival, statistically
significant differences were observed in pathological T,
N, and AJCC stage in univariate analysis. In multivariate
analysis, there were no statistically significant factors.
For disease-free survival, age; pathological T, N, and
AJCC stage; and tumor location were statistically signifi-
cant in univariate analysis. Patients with inner quadrant
tumors showed worse disease-free survival than those
with outer quadrant tumors (79.4% vs 86.4%). In multi-
variate analysis, age and pathological N stage were sta-
tistically significant. 
Regional recurrence pattern according to 
radiotherapy volume
Regional recurrence pattern was analyzed according
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Table 2. Patterns of failure after breast conserving treatment
Recurrences No. of patients %
Local 14 3.8
True 4
Marginal miss 2
Elsewhere 3
Skin 5
Regional 17 4.6
SCL LN 11
IMN 2
SCL LN+IMN 2
Upper neck node 2
Distant metastasis 40 11.0
Contralateral breast cancer 7 1.9
SCL=supraclavicular; LN=lymph node; IMN=internal mammary node.
Table 3. Prognostic factors affecting overall and disease-free
survival
Variables
10-yr overall survival
Rate (%) p-value
10-yr disease-free
survival
Rate (%) p-value
Age (yr)
≤35 79.6 0.069 71.5 0.001
>35 87.6 86.8
Menopausal status
Pre 85.4 0.844 82.3 0.118
Post 88.0 80.0
pT stage
T1 89.4 0.036 86.0 0.033
T2 82.2 77.2
pN stage
N0 89.7 <0.001 90.2 <0.001
N1 86.1 79.5
N2 64.9 67.2
N3 67.1 38.5
AJCC staging
I 90.5 <0.001 89.3 <0.001
IIa 89.5 84.9
IIb 80.3 74.8
IIIa 64.9 67.2
IIIc 44.8 38.5
Chemotherapy
Yes 83.7 0.221 86.1 0.386
No 88.3 81.7
Tumor location
Outer 88.9 0.079 86.4 0.039
Inner 80.5 79.4
AJCC=American Joint Committee on Cancer. 
to radiation volume (Table 4). Among N0 patients who
received irradiation to the breast alone, 11 (4.7%) had
regional recurrence. Four out of 76 (5.2%) N1 patients
who received irradiation to the breast alone experienced
regional recurrences. In patients who received SCL irra-
diation, only 2 showed regional recurrence, 1 of whom
had upper neck nodal recurrence while the other had
IMN recurrence. Both patients had accompanying distant
metastasis and were deceased at 39 and 51 months, res-
pectively. Univariate analyses of factors affecting regional
recurrence in the breast alone radiation group were per-
formed. Age and tumor location were found to be sig-
nificant factors for regional recurrence. In multivariate
analysis, only tumor location remained significant for
regional recurrence. There were ten recurrences (10/81,
12.3%) in upper inner quadrant and one recurrence (1/17,
6%) in lower inner quadrant. When the tumor location
was the inner quadrant, the incidence of regional recur-
rence was higher than the outer quadrant (11.2% vs 1.9%)
(Table 5). The site of regional recurrence in patients with
inner quadrant tumor was in the SCL LN in 7 patients,
in the IMN in 1 patients, in the neck node in 1 patient,
and both in the SCL LN and IMN in 2 patients. 
DISCUSSION
In this study, we report the long-term results of pati-
ents with the majority having more than 10-yr of follow-
up. Our results are comparable to the long-term results
of many other studies.(5-7) Local recurrence rate is low,
but we experienced five cases of skin recurrence. As we
reported previously,(2) skin recurrences occurred early
in patients with extensive axillary LNs metastases. All
the skin recurrences occurred within one year after treat-
ment.Twenty three percent of LN>9 cases had skin recur-
rences. Therefore, application of bolus on intact breast
should be considered in case of extensive nodal metastasis. 
We evaluated the properness of our radiotherapy tech-
nique by analyzing recurrence pattern. We observed a
relationship between tumor location and regional recur-
rence. Regional recurrences were more common in the
patients with tumors in the inner location than patients
with tumors in the outer location. Ten-year overall sur-
vival rate and disease-free survival rate were also worse
in the patients with inner location tumors. Most of pati-
ents with regional recurrences experienced subsequent
distant metastases and in the end succumbed to the can-
cer. Ten out of seventeen (58.8%) developed distant metas-
tasis and died within five years.
Although there was a lack of consensus concerning the
need for irradiation of the regional lymph-node bearing
area, there was an agreement for the necessity to avoid
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Table 4. Regional recurrence according to radiotherapy volume
Volume of radiotherapy No. of regional recurrences %
Breast alone 15/310 4.8
N0 11/233 4.7
N1 4/76 5.2
Unknown 0/1 0
Breast+SCL 2/52 3.8
SCL=supraclavicular.
Table 5. Factors affecting regional recurrence in breast alone
radiation group (n=310)
Variables No. of patients %
Univa-
riate
Multiva-
riate
Age (yr)
≤35 5/53 9.4 0.066 0.227
>35 10/257 3.9
Menopausal status
Pre 10/210 4.8 0.919
Post 5/100 5.0
pT stage
T1 7/186 3.7 0.277
T2 8/124 6.4
pN stage
N0 11/233 4.7 0.963
N1 4/77 5.2
AJCC staging
I 5/149 3.4 0.672
IIa 8/121 6.6
IIb 2/40 5.0
Chemotherapy
Yes 3/124 2.4 0.104 0.215
No 12/186 6.5
Tumor location
Outer 4/212 1.9 <0.001 0.006
Inner 11/98 11.2
AJCC=American Joint Committee on Cancer. 
axillary irradiation after complete axillary dissection. This
was because, not only was the axillary node recurrence
rate after axillary dissection negligibly low, but also axil-
lary irradiation also added morbidities such as arm edema,
breast edema, and brachial plexopathy.(8) In the National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-06
trial and Milan trial in which axillary irradiation was not
performed after axillary dissection even in node positive
patients, regional recurrence was very low ranging from
2.3% to 4.5%.(9,10) These findings support consider the
omission of regional nodal irradiation in patients with
positive axillary LNs. In the report from the Joint Center
for Radiation Therapy, the incidence of axillary failure
for patients undergoing axillary dissection who were
irradiated to the breast only was 2.1% for both patient
group with negative nodes or positive nodes.(11) In the
current study, there was no axillary recurrence. There-
fore, we consistently didn’t irradiate axilla after proper
axillary dissection even in the patient with positive axil-
lary LNs excepting the cases of extracapsular LN exten-
sion. However, the role of axillary dissection has more
recently been controversial. Several prospective random-
ized clinical studies have compared results after axillary
dissection and regional nodal irradiation.(12,13) These
studies show no significant survival difference. Also, the
treatment of the axilla in patients with positive sentinel
nodes is currently a topic of much debate. For this topic,
we need to wait for the results of the large prospective
randomized trial (EORTC 10981).(14)Grills et al.(15) reported
about risk factors for regional failure after BCT. Although
the overall 10-yr regional nodal failure rate was less than
3%, axillary irradiation can significantly reduced the rate
of axillary failure in patients with ≥4 positive nodes. The
only significant predictor of regional nodal failure was
the maximal size of the nodal metastasis. Therefore, a
possible benefit to axillary irradiation in some subset of
patients cannot be completely excluded.
The current standard of care for patients with nega-
tive axillary LNs remains to be whole breast irradiation.
Although accelerated partial breast irradiation has been
developed and proven feasible with acceptable toxicity in
some selective women, it has not yet been demonstrated
in randomized trials.(16,17) And SCL fossa irradiation is
recommended for patients with more than three positive
axillary LNs. However, the data supporting SCL node
irradiation in patients with one to three positive axillary
LNs is insufficient.(18-20)Therefore, we did not treat SCL
fossa irradiation in patients with N0 or N1. And we did
not consider IMN irradiation. Since our results showed that
a considerable number of regional recurrences occurred
in patients with medially located tumors, we began to
recognize the necessity of IMN and SCL fossa irradiation.
However, we don’t have definitive evidence supporting IMN
irradiation in breast-conserving treatment at present.
IMN and SCL LN irradiation is still a controversial issue
in radiotherapy after BCS and postmastectomy radiation
therapy (PMRT). The frequency of IMN involvement in
operable breast cancer patients was variable according
to the existence or lack of axillary LN metastasis. The
rate of IMN metastasis was 6-9% when there was no
axillary LN involvement and 28-52% when there was
axillary LN involvement.(21) Furthermore, it is known
that in case where the tumor is in the inner quadrant,
the frequency of IMN involvement was 12-14% even with-
out axillary LN involvement, which is higher than the
cases where the tumor was in the outer quadrant. In actu-
ality, it is reported that IMN recurrence was very low,
at around 1% clinically.(22) This low incidence might be
due to under-reporting. Buchholz (23) explained this dis-
cordance as follows. IMNs are not palpable by physical
examination and most clinicians do not routinely eval-
uate IMN regions. Since microscopic IMN involvement
has a high risk of developing distant metastases and/or
other local recurrences, these recurrences could mask
IMN recurrence because regional recurrence is not easily
controlled and frequently followed by distant metasta-
sis.(24) Treating IMN metastasis as a subclinical disease
would be worthwhile. 
There are two ongoing trials which are investigating
regional nodal irradiation. The EORTC 10925 trial ran-
domly assigns patients with node-positive or medially
or centrally located tumors to irradiation of the upper
internal mammary and medial SCL nodes or to no nodal
irradiation.(25) The National Cancer Institute of Canada
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Clinical Trials Group MA.20 trial randomly assigns pati-
ents with node-positive or high-risk, node-negative
disease following BCS and adjuvant systemic therapy to
breast irradiation plus regional nodal irradiation or breast
irradiation alone.(26) These trials should address ques-
tions regarding efficacy of additional nodal irradiation
after breast-conserving surgery or mastectomy and the
need to include the internal mammary nodes. Anecdotal
experience supporting IMN irradiation was reported by
Israel.(27) In the high-dose chemotherapy trial for high
risk stage I-II breast cancer, two third of patients received
loco-regional radiotherapy including IMN, but one third
of the patients did not receive the planned IMN irradi-
ation due to the unavailability of the electron beam. As
a result, disease-free survival was significantly prolonged
in patients receiving IMN radiation compared to those
without IMN irradiation (73% vs 52%). 
Predictors of regional recurrence after mastectomy
include short tumor-invaded LNs, large tumor size, and
higher histological grade.(28-30) Similar findings were
observed after breast conservation and young age, lateral
hemispheric lesions, positive LNs, histological grade, and
hormonal receptor status were predictive factors for regi-
onal recurrence.(7,14,24,29) In this study, the regional
recurrence rate in N0 patients who received breast alone
irradiation was only 1.9% when the lesion was localized
to the outer quadrant of the breast. However, the regional
recurrence rate was 11.2% when the lesion was in the inner
quadrant. This was statistically significant (p=0.006).
Although complete pathologic information was not avail-
able to determine the many factors responsible for pati-
ents such as hormonal receptor status, these findings
support internal mammary node irradiation for medially
located tumor. This issue should be evaluated in clinical
trials which contain current chemotherapy and hormone
therapy regimens. 
CONCLUSION
According to our observations, we can conclude that
our techniques of radiotherapy for BCT were relevant to
positive clinical outcomes based on a low recurrence rate
and comparable survival rate. However, in case of inner
quadrant lesion, there were a considerable number of
regional recurrences even in patients with negative axil-
lary LNs. Based on the findings of this study, it could
suggest a potential role for irradiation on regional nodes
(IMN and SCL) for the treatment of patients with inner
quadrant lesions. 
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